

**REMARKS**

Consideration of the captioned application in view of the foregoing amendments and following remarks is requested.

Claims Pending

The claims pending and under consideration are claims 1, 2, 10, 11 and 56-110.

Cancelled Claims 3-9 and 19-55

Claims 3-9 and 19-55 are hereby cancelled without prejudice to, or disclaimer of, the subject matter thereof.

Amendment to the Specification

The Specification is amended at page 9, line 37, to correct for a typographical error. Specifically, the "3" in pyridin-3-yl is corrected to a "5."

Amendment to Claims 1 and 2

Claims 1 and 2 are amended for clarification and to include the language "provided Het<sup>1</sup> is other than 2-substituted-pyridin-5-yl." Support for the amendment is found in the Specification as amended.

Amendment to Claim 10

Claim 10 is amended for clarification and to be presented in independent form.

New Claims 56-110

Original claims 4-9 are represented in amended format (amended to remove multiple dependencies), as claims 56 through 103.

Support for new claim 104 is found as follows:

- "p represents an integer being 0, 1 or 2" (supported by the Specification at page 7 line 37);
- "R<sup>1</sup> independently represents chloro or trifluoromethyl" (supported by the Specification at page 8 line 20);

D

- “R<sup>2</sup> represents Het<sup>1</sup> or C<sub>1-6</sub>alkyl substituted with one or two substituents selected from hydroxy, cyano, amino, mono- or di(C<sub>1-4</sub>alkyl)amino, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylsulfonyloxy, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>3-7</sub>cycloalkyl, aryl, aryloxy, arylthio, Het<sup>1</sup>, Het<sup>1</sup>oxy and Het<sup>1</sup>thio; and if X is O, S or NR<sup>5</sup>, then R<sup>2</sup> may also represent aminocarbonyl, aminothiocarbonyl, C<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkylthiocarbonyl, arylcarbonyl, arylthiocarbonyl, Het<sup>1</sup>carbonyl or Het<sup>1</sup>thiocarbonyl” (supported by the Specification at page 8 lines 3-8);
- “R<sup>11</sup> independently being selected from hydroxy, cyano, nitro, halo, C<sub>1-4</sub>alkyloxy, formyl, NR<sup>7</sup>R<sup>8</sup>, C(=O)NR<sup>7</sup>R<sup>8</sup>, -C(=O)-O-R<sup>14</sup>, aryl, arylcarbonyl, Het<sup>3</sup> and C(=O)Het<sup>3</sup>” (supported by the Specification at page 8 lines 19-20);
- “Het<sup>1</sup> represents a heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup> provided Het<sup>1</sup> is other than 2-substituted-pyridin-5-yl” (supported by original claim 6 and Specification at page 9 lines 23-37 as amended herein);
- “Het<sup>2</sup> represents a heterocycle selected from furanyl, thienyl, pyridinyl or benzothienyl, wherein said aromatic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>4</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with R<sup>11</sup>” (supported by the Specification at page 9 lines 1-4);
- “Het<sup>3</sup> represents a monocyclic heterocycle selected from piperidinyl, piperazinyl, morpholinyl and tetrahydropyranyl each independently and optionally substituted with, where possible, one, two, three or four substituents each independently

selected from hydroxy, C<sub>1-4</sub>alkyl, C(=O)-O-R<sup>14</sup>, C<sub>1-4</sub>alkylcarbonyl, R<sup>6</sup>, piperidinyl and C<sub>1-4</sub>alkyl substituted with one or two substituents independently selected from hydroxy, C<sub>1-4</sub>alkyloxy, C(=O)-O-R<sup>14</sup> and phenyl" (supported by the Specification at page 9 lines 5-9);

- "Het<sup>4</sup> represents a monocyclic heterocycle selected from thienyl or pyridinyl" (supported by the Specification at page 9 line 10).

Support for new claims 105-110 is found in original claims 4-9.

Conclusion

Applicant respectfully requests that a timely Notice of Allowance of claims 1, 2, 10, 11 and 56-110 be issued in this case. The Examiner is cordially invited to contact the undersigned with any questions regarding this application.

Respectfully submitted,

By: Alana G. Kriegsman  
Alana G. Kriegsman, Esq.  
Reg. No. 41,747

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1495  
Dated: June 24, 2003

D